4 unknown, 3 completed, 1 recruiting, 1 withdrawn. 9 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 9 | Unknown 4, Completed 3, Recruiting 1, Withdrawn 1 |
Follow Nucleosides: new trials by email Literature Review of Nucleosides trials Research Report on Nucleosides
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Peginterferon Treatment Study for Inactive Chronic Hepatitis B Patients Peginterferon Alfa-2B, Nucleoside Analogs - Hepatitis B, Chronic | Phase 4 | Recruiting | Third Affiliated Hospital, Sun Yat-Sen University | 5000 | 2022-01-08 | 2025-05-01 |
| Inflammation and Co-Infections in D²EFT NRTIs, Darunavir, Ritonavir - HIV-infection/Aids, Human Herpesvirus 4 Infections | Phase 4 | Withdrawn | Kirby Institute | 2021-02-01 | 2020-11-10 | |
| Body Composition Sub-study of the D2EFT Trial Darunavir (DRV) 800 milligram (MG) Oral Tablet, Ritonavir 100 MG Oral Tablet, N(t)RTIs - HIV Infections | Phase 4 | Completed | Kirby Institute | 155 | 2019-12-05 | 2025-01-09 |
| The Optimizing Treatment of Peginterferon Alpha in Chronic Hepatitis B Patients With Low Level HBsAg Peginterferon Alfa, Nucleoside Analog (Substance) - Chronic Hepatitis B | Phase 4 | Unknown | Third Affiliated Hospital, Sun Yat-Sen University | 200 | 2019-01-01 | 2019-01-15 |
| Dolutegravir and Darunavir Evaluation in Adults Failing Therapy NRTIs, Dolutegravir, Darunavir - HIV Infections | Phase 4 | Unknown | Kirby Institute | 831 | 2017-11-23 | 2023-04-18 |
| To Study the Effect of Adding on Pegylated Interferon (PEG-INF) Therapy for Patients Diagnosed With Chronic Hepatitis B PEG-IFN & Nucleos(t)tide analogues, Nucleos(t)tide analogues - Hepatitis B | Phase 4 | Unknown | King Abdullah International Medical Research Center | 214 | 2015-03-01 | 2018-03-09 |
| Thymalfasin Adjuvant Therapy in Hepatitis B Virus (HBV)-Related Hepatocellular Carcinoma (HCC) After Curative Resection curative resection, thymalfasin, nucleoside analog (suggest to use entecavir) - Curable Hepatitis B Virus-Related Hepatocellular Carcinoma | Phase 4 | Unknown | Jia Fan | 360 | 2015-01-01 | 2014-11-21 |
| Cryptococcal Optimal ART Timing Trial efavirenz, nucleoside - Cryptococcal Meningitis, HIV Infections | Phase 4 | Completed | University of Minnesota | 177 | 2010-11-01 | 2020-06-09 |
| A Trial of 2 Options for Second Line Combination Antiretroviral Therapy Following Virological Failure of a Standard Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)+2N(t)RTI First Line Regimen raltegravir, 2N(t)RTI, Ritonavir-boosted lopinavir - HIV Infections | Phase 4 | Completed | Kirby Institute | 558 | 2009-09-01 | 2026-03-27 |
HIV Infections (4) · Acquired Immunodeficiency Syndrome (3) · Hepatitis B, Chronic (2) · Coinfection (1) · Cryptococcosis (1) · Cytomegalovirus Infections (1) · Epstein-Barr Virus Infections (1) · Hepatitis B (1) · Inflammation (1) · Meningitis, Cryptococcal (1) · Opportunistic Infections (1)
Kirby Institute (4) · Third Affiliated Hospital, Sun Yat-Sen University (2) · Jia Fan (1) · King Abdullah International Medical Research Center (1) · University of Minnesota (1)
South Africa (4) · China (3) · India (3) · Malaysia (3) · Argentina (2) · Chile (2) · Mexico (2) · Nigeria (2) · Thailand (2) · Zimbabwe (2) · Australia (1) · Brazil (1) · Colombia (1) · France (1) · Germany (1)
Abduljaleel Alalwan, MD (1) · Baoshan Yang (1) · Bigang Xiong (1) · Bihua Gao (1) · Bihui Zhong (1) · Bin Liu (1) · Bin Zhou (1) · Binhong Fu (1) · Brian Gazzard, MD (1) · Caihua Jiang (1) · Changxia Niu (1) · Changzheng Hu (1) · Chengfang Zheng (1) · Chengrun Xu (1) · Chengzu Lin (1)
PMID 23769235, PMID 24204757, PMID 24963568, PMID 25723472, PMID 26094695, PMID 26632544, PMID 30325463, PMID 31319498, PMID 31504335, PMID 32843994, PMID 33399309, PMID 38721980, PMID 38788744, PMID 39972326, PMID 40390028, PMID 41779383
U01AI089244 (1)